[go: up one dir, main page]

MX2022015026A - Compuesto heteroaromatico de imidazol de cinco miembros y uso del mismo. - Google Patents

Compuesto heteroaromatico de imidazol de cinco miembros y uso del mismo.

Info

Publication number
MX2022015026A
MX2022015026A MX2022015026A MX2022015026A MX2022015026A MX 2022015026 A MX2022015026 A MX 2022015026A MX 2022015026 A MX2022015026 A MX 2022015026A MX 2022015026 A MX2022015026 A MX 2022015026A MX 2022015026 A MX2022015026 A MX 2022015026A
Authority
MX
Mexico
Prior art keywords
imidazole compound
member heteroaromatic
compound
formula
heteroaromatic
Prior art date
Application number
MX2022015026A
Other languages
English (en)
Inventor
Shuhui Chen
Chengde Wu
Tao Yu
Lu Gan
Original Assignee
Hangzhou Sciwind Biosciences Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hangzhou Sciwind Biosciences Co Ltd filed Critical Hangzhou Sciwind Biosciences Co Ltd
Publication of MX2022015026A publication Critical patent/MX2022015026A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Un compuesto de imidazol heteroaromático de cinco miembros novedoso y su uso en la preparación de un medicamento para el tratamiento de enfermedades relacionadas. Específicamente, se divulga un compuesto como se muestra en la fórmula (III) y una sal farmacéuticamente aceptable del mismo. (ver Fórmula).
MX2022015026A 2020-06-04 2021-06-04 Compuesto heteroaromatico de imidazol de cinco miembros y uso del mismo. MX2022015026A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN202010499820 2020-06-04
CN202010676014 2020-07-14
CN202010838768 2020-08-19
PCT/CN2021/098424 WO2021244645A1 (zh) 2020-06-04 2021-06-04 五元杂芳并咪唑类化合物及其应用

Publications (1)

Publication Number Publication Date
MX2022015026A true MX2022015026A (es) 2023-01-04

Family

ID=78830627

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022015026A MX2022015026A (es) 2020-06-04 2021-06-04 Compuesto heteroaromatico de imidazol de cinco miembros y uso del mismo.

Country Status (13)

Country Link
US (1) US11542272B2 (es)
EP (1) EP4155313B1 (es)
JP (1) JP7359974B2 (es)
KR (1) KR102588241B1 (es)
CN (1) CN115698022B (es)
AU (1) AU2021286086B2 (es)
CA (1) CA3181120C (es)
ES (1) ES3049538T3 (es)
IL (1) IL298753B2 (es)
MX (1) MX2022015026A (es)
NZ (1) NZ796075A (es)
PH (1) PH12022553313A1 (es)
WO (1) WO2021244645A1 (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7558267B2 (ja) 2019-10-25 2024-09-30 ギリアード サイエンシーズ， インコーポレイテッド Ｇｌｐ－１ｒ調節化合物
SI4097097T1 (sl) 2020-01-29 2025-04-30 Gilead Sciences, Inc. Spojine, ki modulirajo glp-1r
US20230203057A1 (en) * 2020-06-04 2023-06-29 Hangzhou Sciwind Biosciences Co., Ltd Five-membered heteroaromatic imidazole compound and use thereof
PE20231181A1 (es) 2020-08-06 2023-08-11 Gasherbrum Bio Inc Agonistas del glp-1 heterociclicos
CN116406360A (zh) 2020-08-28 2023-07-07 加舒布鲁姆生物公司 杂环glp-1激动剂
US11851419B2 (en) 2020-11-20 2023-12-26 Gilead Sciences, Inc. GLP-1R modulating compounds
CN115667238B (zh) * 2020-12-25 2024-08-23 西藏海思科制药有限公司 一种五并五元环衍生物及其在医药上的应用
US12180197B2 (en) 2021-03-11 2024-12-31 Gilead Sciences, Inc. GLP-1R modulating compounds
US12091404B2 (en) 2021-03-11 2024-09-17 Gilead Sciences, Inc. GLP-1R modulating compounds
EP4317145A4 (en) 2021-03-24 2025-03-12 Shionogi & Co., Ltd Pharmaceutical composition containing glp-1 receptor agonist having fused ring
CA3216163A1 (en) 2021-04-21 2022-10-27 Gilead Sciences, Inc. Carboxy-benzimidazole glp-1r modulating compounds
TWI843104B (zh) 2021-05-20 2024-05-21 美商美國禮來大藥廠 類升糖素肽1受體促效劑
CA3224598A1 (en) 2021-08-30 2023-03-09 Long Zhang Novel aryl ether substituted heterocyclic compound as glp1r agonist
US20240374587A1 (en) 2021-09-08 2024-11-14 Shionogi & Co., Ltd. Medicine for prevention and treatment of diseases linked to anti-obesity activity
EP4408840B1 (en) 2021-09-27 2025-08-13 Terns Pharmaceuticals, Inc. Benzimidazole carboxylic acids as glp-1r agonists
WO2023057414A1 (en) 2021-10-05 2023-04-13 Astrazeneca Ab Certain octahydrofuro[3,4- b]pyrazines as glp-1 receptor modulators
US20240417393A1 (en) 2021-10-05 2024-12-19 Astrazeneca Ab Certain 2,5-diazabicyclo[4.2.0]octanes as glp-1 receptor modulators
WO2023057429A1 (en) 2021-10-05 2023-04-13 Astrazeneca Ab Certain 2,5-diazabicyclo[4.2.0]octanes and octahydrofuro[3,4- b]pyrazines as glp-1 receptor modulators
CN118401519A (zh) 2021-10-25 2024-07-26 拓臻制药公司 作为glp-1r激动剂的化合物
US20250154161A1 (en) * 2021-12-03 2025-05-15 Hangzhou Sciwind Biosciences Co., Ltd. Crystal forms of thienoimidazole compound and preparation method thereof
US20250042882A1 (en) 2021-12-16 2025-02-06 Astrazeneca Ab Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators
US20250066338A1 (en) 2021-12-16 2025-02-27 Astrazeneca Ab Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators
WO2023124824A1 (zh) * 2021-12-29 2023-07-06 海思科医药集团股份有限公司 一种glp-1激动剂的盐及其晶型和在医药上的应用
WO2023125896A1 (zh) * 2021-12-31 2023-07-06 海思科医药集团股份有限公司 一种glp-1激动剂中间体及其制备方法及在医药中的用途
CN118613476A (zh) * 2022-01-10 2024-09-06 西藏海思科制药有限公司 一种glp-1激动剂盐及其晶型及在医药上的应用
US12410163B2 (en) 2022-02-23 2025-09-09 Terns Pharmaceuticals, Inc. Compounds as GLP-IR agonists
IL315275A (en) * 2022-02-28 2024-10-01 Ascletis Bioscience Co Ltd Glp-1r modulating compounds
TW202408504A (zh) * 2022-06-23 2024-03-01 大陸商西藏海思科製藥有限公司 噻吩[2,3-d]咪唑類化合物的鹽及其晶型和在醫藥上的用途
CN119730852A (zh) * 2022-06-23 2025-03-28 西藏海思科制药有限公司 一种五并五元环衍生物的药物组合物及其在医药上的应用
CN119907794A (zh) 2022-09-22 2025-04-29 盐野义制药株式会社 具有glp-1受体激动剂作用的稠环化合物
JP2025537254A (ja) 2022-11-11 2025-11-14 イーライ リリー アンド カンパニー グルカゴン様ペプチド１受容体アゴニスト
WO2024107781A1 (en) 2022-11-16 2024-05-23 Eli Lilly And Company Glucagon-like peptide 1 receptor agonists
US20240398794A1 (en) 2023-04-07 2024-12-05 Terns Pharmaceuticals, Inc. COMBINATIONS OF GLP-1R AND THRß AGONISTS AND METHODS OF USE THEREOF
WO2025057134A2 (en) 2023-09-14 2025-03-20 Ascletis Pharma (China) Co., Limited Glp-1r agonist and therapeutic method thereof
US12291530B1 (en) 2023-11-24 2025-05-06 Ascletis Pharma (China) Co., Limited GLP-1R agonist and therapeutic method thereof
WO2025158275A1 (en) 2024-01-24 2025-07-31 Pfizer Inc. Combination therapy using glucose-dependent insulinotropic polypeptide receptor antagonist compounds and glp-1 receptor agonist compounds
KR20250125490A (ko) * 2024-02-14 2025-08-22 주식회사 종근당 Glp-1 수용체 작용제 및 이의 용도
WO2025189141A1 (en) 2024-03-08 2025-09-12 Annapurna Bio, Inc. Methods for treating obesity and increasing weight loss

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013166621A1 (en) * 2012-05-09 2013-11-14 Glaxosmithkline Llc 1-(dihydronaphthalenyl)pyridones as melanin-concentrating hormone receptor 1 antagonists
CR20190289A (es) * 2016-12-16 2019-08-21 Pfizer Agonistas receptores de glp-1 y usos de los mismos
JP7053900B2 (ja) 2018-06-15 2022-04-12 ファイザー・インク Ｇｌｐ－１受容体アゴニストおよびその使用
CN113227068B (zh) 2018-11-22 2023-06-13 上海齐鲁锐格医药研发有限公司 Glp-1r激动剂及其用途
CN119930603A (zh) * 2020-09-01 2025-05-06 江苏恒瑞医药股份有限公司 稠合咪唑类衍生物、其制备方法及其在医药上的应用
CN115667238B (zh) * 2020-12-25 2024-08-23 西藏海思科制药有限公司 一种五并五元环衍生物及其在医药上的应用

Also Published As

Publication number Publication date
US11542272B2 (en) 2023-01-03
NZ796075A (en) 2023-04-28
US20220135588A1 (en) 2022-05-05
ES3049538T3 (en) 2025-12-17
EP4155313A4 (en) 2023-09-13
CN115698022B (zh) 2024-03-15
KR20230016701A (ko) 2023-02-02
JP7359974B2 (ja) 2023-10-11
IL298753A (en) 2023-02-01
CA3181120C (en) 2024-01-02
WO2021244645A1 (zh) 2021-12-09
PH12022553313A1 (en) 2023-04-12
BR112022023879A2 (pt) 2022-12-27
KR102588241B1 (ko) 2023-10-11
EP4155313B1 (en) 2025-08-27
IL298753B2 (en) 2024-05-01
JP2023520260A (ja) 2023-05-16
EP4155313A1 (en) 2023-03-29
CN115698022A (zh) 2023-02-03
AU2021286086B2 (en) 2023-09-07
CA3181120A1 (en) 2021-12-09
AU2021286086A1 (en) 2023-02-09
IL298753B1 (en) 2024-01-01

Similar Documents

Publication Publication Date Title
MX2022015026A (es) Compuesto heteroaromatico de imidazol de cinco miembros y uso del mismo.
AR119207A1 (es) DERIVADOS DE PIRROLO[1,2-c]IMIDAZOL COMO INHIBIDORES DE EGFR
DOP2024000039A (es) Derivados de quinolina como inhibidores de la integrina alfa4beta7
ZA202006378B (en) N-heterocyclic five-membered ring-containing capsid protein assembly inhibitor, pharmaceutical composition thereof, and use thereof
MX391410B (es) Derivados de quinolino-pirrolidin-2-ona como inhibidores del gen mutado de ataxia telangiectasia (atm) y el uso de los mismos en el tratamiento de tumores sólidos.
UY30819A1 (es) Derivados de pirazol, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones
SV2015005115A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
CL2022001724A1 (es) Método y aplicación de preparación de compuesto como agente de degradación de proteínas
CO6390066A2 (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas
ECSP12011799A (es) Compuestos de espiropiperidina y uso farmacéutico de los mismos
MX2015016344A (es) Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades.
WO2013009140A3 (en) 2-pyridyl substituted imidazoles as alk5 and/or alk4 inhibitors
MX346730B (es) Composiciones y metodos para el tratamiento de la hipertension pulmonar.
MX2019003143A (es) Compuesto heterociclico sustituido con alquinilo, su metodo de preparacion y su uso medico.
MX2025000273A (es) Compuesto que contiene nitrogeno y uso del mismo
EA201791289A1 (ru) Ингибиторы клеточного некроза и связанные с ними способы
EA201691058A1 (ru) Производные пирролопирролона и их применение для лечения заболеваний
MX2020003732A (es) Derivado de anillo fusionado como inhibidor del receptor a2a.
AR083575A1 (es) Aminopirazoles para inhibir la proteinquinasa chk1
UY37445A (es) Derivados novedosos de napitridinona y su uso en el tratamiento de la arritmia
EA201692298A1 (ru) Производные карбоксамидов
MX2022004713A (es) Derivados de tiofeno como inhibidores de xantina oxidasa y aplicacion de los mismos.
CL2022002838A1 (es) Derivado de arilo o heteroarilo
MX2024001613A (es) Derivado de oxaspiro, metodo de preparacion del mismo y uso del mismo.
MX2024004273A (es) Derivado triciclico de pirimidina y aplicacion farmaceutica del mismo.